QuickView: Aramchol cleared to start key NASH trial

Galmed’s aramchol is expected to start a Phase IIb study in late 2014 for non-alcoholic steatohepatitis (NASH), an area that has attracted significant investor interest. Over the long term, further NASH studies as well as in non-alcoholic fatty liver disease (NAFLD), cholesterol gallstones and lipodystrophy are also planned. Although aramchol is unlikely to be near first-to-market, data seen to date suggest a competitive market profile.